Comparison of the efficacy of propofol combined with esmketamine and propofol combined with remifentanil in nodynia fiberoptic bronchoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048790

Enrollment

Unknown

Registered

2021-07-16

Start date

2022-07-01

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung disease

Interventions

Propofol combined with remifentanil group:remifentanil

Propofol combined with esketamine group:esmketamine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 65; 2. American Society of anesthesiologists (ASA) grade I ~ II; 3. Mallampatis grade I ~ II; 4. Body mass index (BMI) ranged from 18.5 to 24.

Exclusion criteria

Exclusion criteria: 1.Patients with liver and kidney dysfunction, coagulation dysfunction or mental illness before operation; 2.Severe respiratory insufficiency; 3.History of severe allergy to the drug; 4.Refuse to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Time of consciousness disappearance and recovery;Ramsay sedation score;Vital signs;adverse reaction;Total dosage of propofol;	—

Countries

China

Contacts

Public ContactZhu Zhaoqiong

The Affiliated Hospital of Zunyi Medical University

1625836721@qq.com+86 13885218901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026